LCC
Infuzide : A Promising New Molecule Against Multidrug-Resistant Bacteria
In response to the global health crisis posed by antimicrobial resistance, Michel Baltas (Team R, LCC – Molecules and Composites for Optics) and his collaborators have synthesized a new molecule named infuzide. This compound has demonstrated efficacy against resistant strains of gram-positive pathogens, notably Staphylococcus aureus and Enterococcus, in both laboratory and animal model tests. Infuzide outperformed certain standard antibiotics, marking a significant step forward in the search for new treatments against infections resistant to conventional antibiotics.
Read the American Society for Microbiology press release
Contact :
Michel Baltas Michel.Baltas(at)lcc-toulouse.fr
Structure of Infuzide molecule (C17H14N4O4)
©Michel Baltas / LCC CNRS
Reference :
Comprehensive biological evaluation of infuzide as a potent antimicrobial, alone and in combination with gentamicin, linezolid, and minocycline targeting MDR Staphylococcus aureus and Enterococcus sp.
Maitra R, Saxena D, Akhir A, Kapusterynska A, Baltas M, Chopra S.0.
Microbiol Spectr0:e00279-25.
https://doi.org/10.1128/spectrum.00279-25
Two other publications by Dr Michel Baltas recently recognized:
- ACS Omega 2022 7 (40), 35635-35655 DOI: 10.1021/acsomega.2c03421
Read more on the ACS website: “Lawsone” featured as Molecule of the Week
Read the article “Lawsone featured in ACS Molecule of the Week” on the LCC website
- RSCMechanochemistry, 2024, 1, 167-175. DOI: 10.1039/d3mr00032j
Read the article “One-step synthesis of therapeutic molecules using mechanochemistry“ on the LCC website
Read the article on CNRS Chimie
LCC
Laboratoire de chimie de coordination du CNRS
205 route de Narbonne, BP 44099
31077 Toulouse cedex 4
France
+ 33 5 61 33 31 00
